ACM
ZVRA icon

Altium Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Altium Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,287,333
Closed -$9.64M – 20
2025
Q1 		$9.64M Sell
1,287,333
-562,667
-30% -$4.47M 23.23% 1
2024
Q4 		$15.4M Buy
1,850,000
+150,000
+9% +$1.28M 4.38% 4
2024
Q3 		$11.8M Buy
1,700,000
+537,584
+46% +$3.65M 3.47% 6
2024
Q2 		$5.7M Buy
1,162,416
+820,955
+240% +$3.89M 2.32% 18
2024
Q1 		$1.98M Buy
+341,461
New +$2.1M 0.78% 34

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Altium Capital Management's ZVRA Position: Q2 2025 in Review

Altium Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2025, closing a stake of 1,287,333 shares — an estimated $9.64M sold.

Altium Capital Management first reported a position in ZVRA in Q1 2024 and held it in 5 quarters. The position peaked at $15.4M in Q4 2024. 120 funds tracked by Wall St. Rank hold ZVRA as of Q2 2025.

  • Altium Capital Management reported no remaining Zevra Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 1,287,333 Zevra Therapeutics shares in Q2 2025, an estimated $9.64M.
  • Altium Capital Management first reported a position in Zevra Therapeutics in Q1 2024 and held it in 5 quarters.
  • Altium Capital Management's Zevra Therapeutics position peaked at $15.4M in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.